| Citation: |
YUAN Zhiying, MA En, WO Da, PENG Jun, ZHU Weidong, REN Danni. Berberine Promotes Mouse Breast Cancer Metastasis to Lung via Inducing Epithelial–mesenchymal Transition[J]. Cancer Research on Prevention and Treatment, 2023, 50(8): 753-759. DOI: 10.3971/j.issn.1000-8578.2023.23.0284
|
To study the effect and mechanism of berberine (BBR) on the lung metastasis of mouse breast cancer via epithelial-mesenchymal transition (EMT).
CCK-8 and Transwell migration assays were utilized to investigate the proliferation and migration properties of breast cancer 4T1 cells after BBR treatment.Mouse 4T1-Luc cells were injected into mice under the fourth mammary fat pad, and the mice were then randomly divided into the control and BBR groups.The mice in the BBR group received daily intraperitoneal injections of BBR working solution and those in the control group were continuously intraperitoneally injected with the same volume of the solvent used to dissolve BBR powder.Tumor metastasis in the lungs of living mice was detected by using an in vivo imaging system.After 42 days of administration, lung metastasis was measured via microscopy and HE staining.Western blot analysis was used to examine the effects of BBR on the expression of EMT-related proteins (Vimentin and Snail) as well as the activation of the Akt and ERK signaling pathways.
BBR significantly promoted 4T1 cell migration (P < 0.05).In vivo experiments showed that the number of lung metastases in the BBR group had significantly increased compared with that in control group (P < 0.05) as observed under microcopy and histological staining.Compared with the control group, BBR upregulated the expression levels of Vimentin and Snail as well as the phosphorylated levels of p-Akt and p-ERK (P < 0.05).
BBR may promote EMT and lung metastasis of breast cancer 4T1 cells by activating the expression of proteins in the p-Akt and p-ERK pathways.
Competing interests: The authors declare that they have no competing interests.
| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidenceand Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
|
| [2] |
Yousefi M, Nosrati R, Salmaninejad A, et al. Organ-specific metastasis of breast cancer: molecular and cellular mechanisms underlying lung metastasis[J]. Cell Oncol (Dordr), 2018, 41(2): 123-140.
|
| [3] |
Buyuk B, Jin S, Ye K. Epithelial-to-Mesenchymal Transition Signaling Pathways Responsible for Breast Cancer Metastasis[J]. Cell Mol Bioeng, 2022, 15(1): 1-13. doi: 10.1007/s12195-021-00694-9
|
| [4] |
De Luca A, Maiello MR, D'Alessio A, et al. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches[J]. Expert Opin Ther Targets, 2012, 16 Suppl 2: S17-S27.
|
| [5] |
滕磊, 柴宇琪, 忻耀杰, 等. 基于《长沙药解》探析黄芩、黄连和黄柏的临床效用之别[J]. 上海中医药大学学报, 2018, 32(2): 7-10. https://www.cnki.com.cn/Article/CJFDTOTAL-SHZD201802003.htm
Teng L, Chai YQ, Xin YJ, et al. Discussion of differences on clinical efficacy and application among Huangqin (Scutellariae Radix), Huanglian (Coptidis Rhizoma) and Huangbo (Phellodendri Chinensis Cortex) based on Changsha Yaojie (Changsha Drug Analysis)[J]. Shanghai Zhong Yi Yao Da Xue Xue Bao, 2018, 32(2): 7-10. https://www.cnki.com.cn/Article/CJFDTOTAL-SHZD201802003.htm
|
| [6] |
王小兰, 幸尚平, 肖建勇, 等. 左金方及其主要成分小檗碱对人胃癌细胞SGC7901上皮间质转化的影响[J]. 中国实验方剂学杂志, 2018, 24(12): 62-67. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSFX201812011.htm
Wang XL, Xing SP, Xiao JY, et al. Effect of Zuojinfang and Its Main Ingredient Berberine on Epithelial Mesenchymal Transition of Human Gastric Cancer Cell Line SGC7901[J]. Zhongguo Shi Yan Fang Ji Xue Za Zhi, 2018, 24(12): 62-67. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSFX201812011.htm
|
| [7] |
陈宁宁, 蒋义芳, 杨懿, 等. 小檗碱与吴茱萸碱联用对结直肠癌细胞迁移、侵袭能力的影响[J]. 中国实验方剂学杂志, 2022, 28(24): 98-104. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSFX202224012.htm
Chen NN, Jiang YF, Yang Y, et al. Effect of Berberine Combined with Evodiamine on Migration and Invasion of Colorectal Cancer Cells[J]. Zhongguo Shi Yan Fang Ji Xue Za Zhi, 2022, 28(24): 98-104. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSFX202224012.htm
|
| [8] |
Zheng F, Li J, Ma C, et al. Novel regulation of miR-34a-5p and HOTAIR by the combination of berberine and gefitinib leading to inhibition of EMT in human lung cancer[J]. J Cell Mol Med, 2020, 24(10): 5578-5592. doi: 10.1111/jcmm.15214
|
| [9] |
Esteva FJ, Hubbard-Lucey VM, Tang J, et al. Immunotherapy and targeted therapy combinations in metastatic breast cancer[J]. Lancet Oncol, 2019, 20(3): e175-e186. doi: 10.1016/S1470-2045(19)30026-9
|
| [10] |
Baumann Z, Auf der Maur P, Bentires-Alj M. Feed-forward loops between metastatic cancer cells and their microenvironment-the stage of escalation[J]. EMBO Mol Med, 2022, 14(6): e14283. doi: 10.15252/emmm.202114283
|
| [11] |
Lee YH, Kim D, Lee MJ, et al. Subchronic toxicity study of Coptidis rhizoma in rats[J]. J Ethnopharmacol, 2014, 152(3): 457-463. doi: 10.1016/j.jep.2014.01.011
|
| [12] |
Wang J, Wang L, Lou GH, et al. Coptidis Rhizoma: a comprehensive review of its traditional uses, botany, phytochemistry, pharmacology and toxicology[J]. Pharm Biol, 2019, 57(1): 193-225. doi: 10.1080/13880209.2019.1577466
|
| [13] |
Li SY, Shi CJ, Fu WM, et al. Berberine inhibits tumour growth in vivo and in vitro through suppressing the lincROR-Wnt/beta-catenin regulatory axis in colorectal cancer[J]. J Pharm Pharmacol, 2023, 75(1): 129-138. doi: 10.1093/jpp/rgac067
|
| [14] |
McCubrey JA, Abrams SL, Steelman LS, et al. APR-246-The Mutant TP53 Reactivator-Increases the Effectiveness of Berberine and Modified Berberines to Inhibit the Proliferation of Pancreatic Cancer Cells[J]. Biomolecules, 2022, 12(2): 276. doi: 10.3390/biom12020276
|
| [15] |
Xu M, Ren L, Fan J, et al. Berberine inhibits gastric cancer development and progression by regulating the JAK2/STAT3 pathway and downregulating IL-6[J]. Life Sci, 2022, 290: 120266. doi: 10.1016/j.lfs.2021.120266
|
| [16] |
Sung JH, Kim JB, Park SH, et al. Berberine decreases cell growth but increases the side population fraction of H460 lung cancer cells[J]. J Korean Soc Appl Biol Chem, 2012, 55: 491-495. doi: 10.1007/s13765-012-2119-0
|
| [17] |
Zheng X, Zhao Y, Jia Y, et al. Biomimetic co-assembled nanodrug of doxorubicin and berberine suppresses chemotherapy-exacerbated breast cancer metastasis[J]. Biomaterials, 2021, 271: 120716. doi: 10.1016/j.biomaterials.2021.120716
|
| [18] |
Refaat A, Abdelhamed S, Yagita H, et al. Berberine enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast cancer[J]. Oncol Lett, 2013, 6(3): 840-844. doi: 10.3892/ol.2013.1434
|
| [19] |
Calabrese EJ. Hormesis: why it is important to toxicology and toxicologists[J]. Environ Toxicol Chem, 2008, 27(7): 1451-1474. doi: 10.1897/07-541.1
|
| [20] |
Wei C, Khan MA, Du J, et al. Cordycepin Inhibits Triple-Negative Breast Cancer Cell Migration and Invasion by Regulating EMT-TFs SLUG, TWIST1, SNAIL1, and ZEB1[J]. Front Oncol, 2022, 12: 898583. doi: 10.3389/fonc.2022.898583
|
| [21] |
Ghalavand M, Dorostkar R, Borna H, et al. MicroRNA-122 Is More Effective than Rapamycin in Inhibition of Epithelial-mesenchymal Transition and mTOR Signaling Pathway in Triple Negative Breast Cancer[J]. Iran J Allergy Asthma Immunol, 2023, 22(1): 46-61.
|
| [22] |
André F, Zielinski CC. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents[J]. Ann Oncol, 2012, 23 Suppl 6: vi46-vi51.
|
| [23] |
Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression[J]. Curr Opin Cell Biol, 2005, 17(5): 548-558.
|
| [24] |
Usman S, Waseem NH, Nguyen TKN, et al. Vimentin Is at the Heart of Epithelial Mesenchymal Transition (EMT) Mediated Metastasis[J]. Cancers (Basel), 2021, 13(19): 4985.
|
| [25] |
Naderi R, Gholizadeh-Ghaleh Aziz S, Haghigi-Asl AS. Evaluating the effect of Alantolactone on the expression of N-cadherin and Vimentin genes effective in epithelial-mesenchymal transition (EMT) in breast cancer cell line (MDA-MB-231)[J]. Ann Med Surg (Lond), 2022, 73: 103240.
|
| [26] |
Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy[J]. Cell Mol Life Sci, 2011, 68(18): 3033-3046.
|
| [27] |
Dong B, Wu Y. Epigenetic Regulation and Post-Translational Modifications of SNAI1 in Cancer Metastasis[J]. Int J Mol Sci, 2021, 22(20): 11062.
|
| [28] |
Kielbik M, Szulc-Kielbik I, Klink M. Impact of Selected Signaling Proteins on SNAIL 1 and SNAIL 2 Expression in Ovarian Cancer Cell Lines in Relation to Cells'Cisplatin Resistance and EMT Markers Level[J]. Int J Mol Sci, 2021, 22(2): 980.
|
| [29] |
Smith BN, Odero-Marah VA. The role of Snail in prostate cancer[J]. Cell Adh Migr, 2012, 6(5): 433-441.
|
| [30] |
Shin SW, Choi C, Kim H, et al. MnTnHex-2-PyP (5+), Coupled to Radiation, Suppresses Metastasis of 4T1 and MDA-MB-231 Breast Cancer via AKT/Snail/EMT Pathways[J]. Antioxidants (Basel), 2021, 10(11): 1769.
|
| [31] |
Wei C, Khan MA, Du J, et al. Cordycepin Inhibits Triple-Negative Breast Cancer Cell Migration and Invasion by Regulating EMT-TFs SLUG, TWIST1, SNAIL1, and ZEB1[J]. Front Oncol, 2022, 12: 898583.
|
| [32] |
Bao S, Ji Z, Shi M, et al. EPB41L5 promotes EMT through the ERK/p38 MAPK signaling pathway in esophageal squamous cell carcinoma[J]. Pathol Res Pract, 2021, 228: 153682.
|
| [33] |
De Luca A, Maiello MR, D'Alessio A, et al. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches[J]. Expert Opin Ther Targets, 2012, 16 Suppl 2: S17-S27.
|
| [34] |
孙宇, 邹燕鹏, 邓素华, 等. 不同分子分型乳腺癌原发灶内CD4+、CD8+ T淋巴细胞的表达差异研究[J]. 中国临床研究, 2016, 29(2): 153-156, 161. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGCK201602004.htm
Sun Y, Zou YP, Deng SH, et al. Difference of CD4+ and CD8+ T lymphocytes expressions in primary lesions of different molecular classification breast cancer[J]. Zhongguo Lin Chuang Yan Jiu, 2016, 29(2): 153-156, 161. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGCK201602004.htm
|
| [35] |
欧小波, 周密. ADAM15、MMP-2和MMP-9在不同转移能力乳腺癌细胞系中的表达差异[J]. 基础医学与临床, 2016, 36(2): 227-231. https://www.cnki.com.cn/Article/CJFDTOTAL-JCYL201602016.htm
Ou XB, Zhou M. The expression of ADAM15, MMP-2 and MMP-9 in different breast cancer cell lines[J]. Ji Chu Yi Xue Yu Lin Chuang, 2016, 36(2): 227-231. https://www.cnki.com.cn/Article/CJFDTOTAL-JCYL201602016.htm
|
Figures(4)
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: